Article Figures & Data
Figures
- Figure 1.
Diabetes-related outcome 10-y risk estimates for patient D.K.
Tables
- Table 1.
Excerpt from the decision aid’s FAQ section* outlining the evidence for medication options that reduce the risk of adverse kidney outcomes in patients with T2DM
TREATMENT RR FOR OUTCOMES IN PATIENTS WITH T2DM DEATH ASCVD HEART FAILURE KIDNEY FAILURE SEVERE VISION LOSS NEUROPATHY ACE inhibitors or ARBs 0.75 0.75 0.80 No albuminuric CKD: NA
Albuminuric CKD: 0.60NA NA Finerenone 0.90 (RR=1.00 if eGFR ≥60 mL/min/1.73 m2 and ACR ≤30 mg/mmol) 1.00 0.80 (RR=1.00 if eGFR ≥60 mL/min/1.73 m2 and ACR ≤30 mg/mmol) 0.85 (RR=1.00 if eGFR ≥60 mL/min/1.73 m2 and ACR ≤30 mg/mmol) NA NA GLP1 receptor agonists 0.90 0.90 1.00 0.85 NA 1.00 SGLT2 inhibitors 0.90 0.90 0.65 No albuminuric CKD: 0.70
Albuminuric CKD: 0.65NA 1.00 ACE—angiotensin-converting enzyme, ACR—albumin-creatinine ratio, ARB—angiotensin receptor blocker, ASCVD—atherosclerotic cardiovascular disease, CKD—chronic kidney disease, eGFR—estimated glomerular filtration rate, FAQ—frequently asked questions, GLP1—glucagonlike peptide-1, NA—not applicable (owing to absence of evidence), RR—relative risk, SGLT2—sodium-glucose cotransporter-2, T2DM—type 2 diabetes mellitus.
↵* See the FAQ section for an up-to-date list of references: https://decisionaid.ca/diabetes/faq.html.
